1. Home
  2. SHMD vs ADAG Comparison

SHMD vs ADAG Comparison

Compare SHMD & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SCHMID Group N.V. Class A Ordinary Shares

SHMD

SCHMID Group N.V. Class A Ordinary Shares

HOLD

Current Price

$7.46

Market Cap

301.4M

Sector

N/A

ML Signal

HOLD

Logo Adagene Inc.

ADAG

Adagene Inc.

N/A

Current Price

$3.68

Market Cap

254.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SHMD
ADAG
Founded
1864
2011
Country
Germany
China
Employees
676
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
301.4M
254.4M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
SHMD
ADAG
Price
$7.46
$3.68
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$8.25
AVG Volume (30 Days)
1.1M
95.1K
Earning Date
05-15-2026
04-01-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.00
$1.44
52 Week High
$10.65
$4.75

Technical Indicators

Market Signals
Indicator
SHMD
ADAG
Relative Strength Index (RSI) 62.03 50.91
Support Level $5.29 $3.35
Resistance Level $9.55 $3.99
Average True Range (ATR) 0.69 0.32
MACD 0.17 0.01
Stochastic Oscillator 75.43 66.46

Price Performance

Historical Comparison
SHMD
ADAG

About SHMD SCHMID Group N.V. Class A Ordinary Shares

Schmid Group NV is a global supplier of equipment, software and services for various industries such as printed circuit board (PCB), substrate manufacturing, photovoltaics, and glass and energy storage with a focus on the highest end of this market in terms of technology and performance. It focuses on a modular product portfolio of machinery to use in the manufacturing of high-end PCB equipment and semiconductor packaging devices which includes common flexible circuit fabrication techniques such as subtractive, semi-additive processes (SAP) and modified semi-additive processes (mSAP).

About ADAG Adagene Inc.

Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.

Share on Social Networks: